Check out our executive chairman Lou on Cheddar News Friday: Vaxxinity Wants to Bring Accessible Vaccines for Chronic Illness to Market. https://lnkd.in/exRFc5zt
Vaxxinity
Biotechnology Research
Cape Canaveral, Florida 4,915 followers
Our mission is to democratize health by pioneering the third biologic revolution
About us
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology platform has enabled the innovation of synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic diseases, including Alzheimer's, Parkinson’s, migraine, and hypercholesterolemia.. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health. The key to the platform is the proprietary library of UBITh peptides, which are immunosilent, avoiding inflammation, and when linked to custom-designed target antigens, can elicit highly specific antibodies.
- Website
-
http://www.vaxxinity.com
External link for Vaxxinity
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cape Canaveral, Florida
- Type
- Privately Held
Locations
-
Primary
Get directions
505 Odyssey Way, Exploration Park
Cape Canaveral, Florida 32953, US
Employees at Vaxxinity
-
Derek Collison
Founder & CEO at Synadia. Creator of NATS.io
-
Peter H. Diamandis
Peter H. Diamandis is an Influencer Working to inspire and guide entrepreneurs to create a hopeful, compelling, and abundant future for humanity #mymtp
-
Jason Pesile MBA, CPA
Pharma / Biotech Finance Executive
-
Susan Hensley, MS, RAC
Vice President, Regulatory Affairs/Operations @ Vaxxinity | RAC-US
Updates
-
Vaxxinity reposted this
Will there ever be a cure for Alzheimer’s disease? As the population ages, Alzheimer’s disease is more prevalent. Will treatment ever be effective enough or will prevention be key? - https://lnkd.in/e323TimZ On World Alzheimer's Day we spoke to Dr Dennis Selkoe, the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School, Dr George Perry, a professor of biology and chemistry at the University of Texas, San Antonio, Dr Andrew Saykin, director of the Indiana Alzheimer’s Disease Research Centre Dr Stephen Arnold, neurologist at Mass General Research Institute and professor at Harvard Medical School, Dr Tomasso Croese, an employee of Professor Schwartz’s research group, Mei Mei Hu CEO of Vaxxinity, John McDonough Executive chair at Sunbird Bio to learn more. ` #alzheimers #worldalzheimersday #clinicaltrials
Will there ever be a cure for Alzheimer’s disease?
clinicaltrialsarena.com
-
Our CEO, Mei Mei, has been recognized on the PharmaVoice 100 list as an inspiring leader in the life-sciences space! https://lnkd.in/gFaYzSW6
-
-
Join us online next Monday, 9/11 at 10am ET! You won’t want to miss the latest corporate update from our CEO. Watch live here: https://lnkd.in/gyVnZEy7
Journey
journey.ct.events
-
Looking forward to presenting in September. Our H.C. Wainwright & Co., LLC presentation will be broadcast live to the public. Tune in! https://lnkd.in/gKmcP7M4
-
-
Vaxxinity reposted this
Exploring the potential of immunization strategies to slow cognitive decline in #AD! Vaxxinity Stay updated on innovative approaches in neurology that could shape the future of #Alzheimer treatments: https://ow.ly/nybk50PArri
-
-
Thought leader Dr. Jeff Cummings sums up our latest publication in The Lancet’s eBioMedicine about UB-311, the active vaccine candidate targeting beta-amyloid. https://lnkd.in/gPZWjnES
-
We are proud disrupters! Listen to our CEO, Mei Mei, on Health Professional Radio talk about how Vaxxinity is disrupting medicine.
Vaxxinity - Expansively Disrupting Medicine Read more: https://bit.ly/3OnDFuF #ChronicDiseaseVaccines
Vaxxinity - Expansively Disrupting Medicine
https://healthprofessionalradio.com.au
-
Pleased to announce Vaxxinity's Justin Boyd, Ph.D. will speak at the inaugural Translatable Models in Neuroscience Summit alongside other key leaders in the field.
🌟 Exciting Announcement! Join the Inaugural Translatable Models in Neuroscience Meeting and Transform CNS Drug Development! 🧠💡 CNS drug development is entering a remarkable new era of progress, thanks to ground-breaking modelling technology that revolutionizes our understanding of neurological biology and pathology. Witness the emergence of state-of-the-art in vitro models in 2023, with unprecedented production, ease of use, and biological relevance. Combine them with novel in vivo models and powerful in silico computational tools, and we'll transform basic and translational neurological research. Unite with 50+ pharma and biotech experts who share the goal of producing cost-effective, translatable, and predictive neurological models. Don't miss this catalyst for innovation and collaboration, paving the way for transformative advancements in CNS drug development. Highlights you can't afford to miss: 1️⃣ Explore the latest advances in in-vivo mouse models and neurodegenerative disease models with esteemed speakers from Biogen and Eli Lilly and Company. 2️⃣ Address practical considerations in implementing in vitro models from academic protocols or off-the-shelf solutions. Gain insights from Quiver Bioscience and Vaxxinity. 3️⃣ Disrupt traditional approaches, embrace computational methods, and bolster clinical trial design with AI and ML pioneers from Sanofi and Takeda. 4️⃣ Overcome limitations in understanding CNS models and unlock critical data for toxicity and pharmacokinetic profiles using cutting-edge organ-on-a-chip technology. Benefit from Alchemab Therapeutics Ltd and Regeneron's expertise. 5️⃣ Engage in roundtable discussions bridging mathematical and biological aspects of neuroscience, exploring unified models and pre-competitive sharing opportunities. Network with industry leaders, exchange knowledge, and shape the future of CNS drug development. Let's advance neuroscience and improve lives worldwide. Register now to secure your spot at the forefront of this exciting journey. Unlock the potential of translatable models in neuroscience together! Download the brochure here: https://lnkd.in/eAcibjWh For more information, please message me: julia.lenkiewicz@hansonwade.com Access our website here: https://lnkd.in/eRuiZV6f #CNSDrugDevelopment #NeuroscienceInnovation #TranslatableModels #BiopharmaCollaboration #researchadvancements Laura Dyamond
Event Guide- Translatable Models in Neuroscience Summit 2023
linkedin.com
-
Another win for our UB-312 program! Read the full release here: https://lnkd.in/gjg4u7Gi.
-